If you have been watching Sarepta Therapeutics (SRPT), this week's headlines have probably caught your eye. Multiple law firms have announced class action lawsuits against the company, following ...

Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

The debt refinancing follows the firm's recent trouble with the FDA and efforts to refocus its pipeline priorities, preserve resources, and meet financial obligations.

Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy ...

After deaths and FDA setbacks, Sarepta abandoned LGMD gene therapy, leaving families desperate and patients without ...

Some experts worry that patient groups’ growing influence is leading to the approval of drugs that may not work and could ...

Sarepta Therapeutics obtained traditional FDA approval for ambulatory DMD patients and accelerated approval for ...

Sarepta Therapeutics Inc. landed a deal with investors to restructure around $700 million of debt, giving the company a ...

In the wake of multiple patient deaths from liver injuries related to Sarepta Therapeutics’ AAV gene therapy platform, some ...

With a strong launch underway for a bladder cancer gene therapy, Ferring is finding the kind of commercial success that’s ...

A refinancing deal will delay the maturity of $700 million in debt until 2030, allowing the company to “fully fund” its ...

Sarepta Therapeutics said Friday that the deaths of two patients taking its marketed gene therapy Elevidys® (delandistrogene ...